-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, Bristol-Myers Squibb's (BMS) potential blockbuster deucvacitinib encountered its first setback.
In this clinical trial, 131 patients with moderate to severe ulcerative colitis were randomly assigned to receive oral TYK2 inhibitor deucvacitinib or placebo for 12 weeks
The media reported that Bristol-Myers Squibb downplayed the major setbacks of the deucvacitinib trial and reiterated its forecast that the sales of deucvacitinib in 2029 will exceed 4 billion U.
Even so, the failure of the first mid-term ulcerative colitis study of deucravacitinib was undoubtedly a setback for Bristol-Myers Squibb's decision to uninstall the Otezla drug candidate
Bristol-Myers Squibb’s confidence in deucravacitinib has also paid off, as the drug defeated Otezla in the Phase 3 psoriasis trial
The drug is a new generation Tyk2 small molecule inhibitor developed by Bristol-Myers Squibb
Researchers are now recruiting patients with diseases such as Crohn’s disease, psoriatic arthritis and lupus to participate in phase 2 and phase 3 clinical trials of the therapy
Reference source:
Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster
https://
